AUPH

14.7001.28%
CA

Craig A. Johnson

Lead Independent Director

Mr. Craig A. Johnson is Independent Director of Tang Capital Acquisition Corp. from August 14, 2026. Mr. Johnson serves as an Independent Director of Aurinia Pharmaceuticals Inc. since November 7, 2024 and serves as its Lead Independent Director. He serves as Director at Tetraphase Pharmaceuticals, Inc. since July 28, 2020. He has been a Director at Odonate Therapeutics, Inc. since July 2017. He also serves as a director of Odonate, Inc. He has served as a director of Aurina Pharmaceuticals Inc. since 2024. Mr. Johnson served as an Independent Director of Mirati Therapeutics, Inc. since September 4, 2013 until January 23, 2024 and served as an Independent Director of La Jolla Pharmaceutical Company since October 14, 2013 until August 22, 2022. He served as a Consultant at Adamis Pharmaceuticals Corporation. Mr. Johnson serves as a Lead Independent Director of Heron Therapeutics, Inc. and is its Independent Director since January 13, 2014 and was its Lead Independent Director since October 13, 2020. Mr. Johnson served as the Chief Financial Officer of PURE Bioscience, Inc. from August 1, 2011 to May 4, 2012 and served as its Principal Accounting Officer. He has more experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. He served as the Chief Financial Officer, Senior Vice President and Company Secretary of Novadel Pharma Inc. from June 16, 2010 to July 31, 2011 and served as its Principal Accounting Officer. He served as the Chief Financial Officer and Vice President of Finance of TPTX Inc., a subsidiary of TorreyPines Therapeutics from January 2004 to April 2010. He served as the Chief Financial Officer of Raptor Pharmaceuticals, Corp. and served as its Vice President since 2009 until 2010. He served as Vice President of Finance at TorreyPines Therapeutics, Inc. since October 2006 and its Principal Accounting Officer and Secretary. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 to September 2009. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., most recently as Chief Financial Officer and Senior Vice President of Operations. He served as a Senior Financial Executive for several early-stage technology companies. In his career, he practiced as a CPA with PricewaterhouseCoopers. From 1984 to 1988, he worked for the Accounting firm Price Waterhouse LLP (now PricewaterhouseCoopers LLP). He served as the First President of ABFO International. He served as a Director of Decipher Biosciences, Inc. since October 15, 2015 until 2018. He served as a Director of GenomeDx Biosciences, Incorporatedfrom 2015 to 2018. He served as a Director of Ardea Biosciences, Inc. since June 2008 until its acquisition by AstraZeneca PLC in 2012. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies. He has experience as an Executive Officer and as a Director of numerous life sciences companies. He served as a Director of Adamis Pharmaceuticals Corporation from February 16, 2011 to August 2014. Mr. Johnson holds BBA degree in Accounting from the University of Michigan-Dearborn and is a Certified Public Accountant. He has experience as a Director of biotechnology companies and he is expertise in financial management.

Positions